(University of North Carolina Health Care) A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.

Related Links:

“Are you sure she needs this surgery?” my brother asked my surgeon minutes before the doctor entered the operating room. My brother was suspicious of Western medicine’s harsh approaches to treating cancer.
“If she doesn’t have this surgery, she’ll be dead in three months,” the surgeon said sternly, put out that my brother would even question his authority.
I would learn of this conversation several days after my operation to remove an angiosarcoma on my right breast. The angiosarcoma had resulted from radiation treatment I’d had to eliminate another breast cancer four years b…

Source: World of PsychologyCategory: Psychiatry & Psychology Authors: Tags: Agitation Bipolar Celebrities Depression Suicide Bipolar Disorder Depressive Episode kate spade Source Type: blogs

In this report, we describe a case of RAAS, and employed immunohistochemical (IHC) staining of PD-L1 and MMP9 as well as periostin, IL-4, and CD163. Interestingly, IHC staining revealed that the RAAS in our case was positive for PD-L1 and negative for MMP9. Moreover, the predominant stromal factor of our case was periostin, suggesting that TAMs in the present case was not immunosuppressive, but an inflammatory subtype. These results might explain, at least in part, the better prognosis of RAAS compared to CAS.Case Rep Oncol 2018;11:330 –335

Conclusions:Combination of SUVmax with TLR could accurately differentiate malignant from benign cardiac tumors by using 18F-FDG PET/CT. Research Support: Natural Science Foundation of China (NO.81571717, NO.81071177) Table1. Comparison of SUVmax and TLR in patients with benign and malignant cardiac tumorSUVmaxTLRBenignMalignantBenignMalignant1h (n=15)Delay(n=8)1h (n=23)Delay(n=17)1h (n=15)Delay(n=8)1h (n=23)Delay(n=14)Mean ± SD(range)2.73±1.53[asterisk](0.5~5.4)3.04±1.96[asterisk](0.8~7.2)11.10±6.41(3.8~31.6)15.76±8.16[asterisk][asterisk](6.2~34.1)0.74±0.33[asterisk] (0.2~1.4)0.97 …

Source: Journal of Nuclear MedicineCategory: Nuclear Medicine Authors: Tags: Other Solid Tumors Posters Source Type: research

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.

Source: JDDGCategory: Dermatology Authors:

We describe a case of Guillain –Barré syndrome (GBS) in a patient treated with bevacizumab. Our case is a 60-year-old woman with Stewart–Treves syndrome (STS), and angiosarcoma of her left forearm, with onset 12 years after diagnosis with stage IIIA left breast cancer. She suffered from repeated distal metastases including skin, bone, and liver metastases. She underwent numerous treatments including left arm amputation, radiation, and chemotherapy, but her disease was resistant. Thereafter, she received bevacizumab. Two weeks following the first administration, she presented in poor physical conditi…

In conclusion, MYC amplification and MYC overexpression were detected almost exclusively in secondary AS. No associations were found between MYC amplification/overexpression and prognosis. We found MYC amplification or overexpression in a similar proportion of the patients who died and who were still alive at the end of the study. In the group of 9 patients who died, MYC was detected by FISH in 4 cases and by IHC in 5. The corresponding figures in the group of 6 patients still alive were 2 by FISH and 3 by IHC.

Radiogenic angiosarcoma of the breast (RASB) is a rare late sequela of local irradiation of the breast or chest wall after breast cancer. The prognosis of women with RASB is poor and there is no standardized t…

Source: BMC CancerCategory: Cancer & Oncology Authors: Tags: Case report Source Type: research

Conclusion Our case reports the possibility that metastases of breast cancer might also mimic these conditions.

In the last couple of decades, breast conservation therapy, which utilizes a combination of surgery, radiotherapy, and endocrine or chemotherapy, has become the standard of care for treating early-stage breast cancer. This practice has been greatly beneficial in the improvement of the patient ’s quality of life but has also led to the increased use of radiotherapy and associated soft-tissue sarcomas, with angiosarcoma being the most common malignancy. Radiation-associated angiosarcoma (RAS) of the breast is a rare phenomenon, which has been reported to occur in approximately 0.9 out of 1,000 cases, with a reported on…

Conclusions: While radiation-associated breast angiosarcomas are relatively uncommon, their prognosis is very poor. These data demonstrate a mutational pattern associated with genes involved in DNA repair. While important in revealing the biology behind these tumors, it may also suggest new treatment strategies that will prove successful.
PMID: 29515789 [PubMed]

Source: OncotargetCategory: Cancer & Oncology Tags: Oncotarget Source Type: research





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image